V CompBrief BY VELARION

Executive Vice President and Chief Medical Officer · MADRIGAL PHARMACEUTICALS, INC. (MDGL)

David Soergel

FY2025 is the first fiscal year CompBrief holds for David Soergel as a named executive officer of MADRIGAL PHARMACEUTICALS; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Velarion Intel: free for 3 days, no card →

Total disclosed compensation, FY2025

$9,190,678

2nd of 6 named executive officers at Madrigal Pharmaceuticals by FY2025 total.

6 named officers on file for MADRIGAL PHARMACEUTICALS, FY2025

See an example →

What this number hides

The filing gives the total. MADRIGAL PHARMACEUTICALS’s full Executive Compensation Report gives every award, the disclosed peer set and what the total leaves out — the pair adds the board’s.

Velarion Intel · free for 3 days · no card

See how MADRIGAL PHARMACEUTICALS’s whole pay program stands against its peers

  • MADRIGAL PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on MDGL→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2026 (DEF 14A). Insider transactions since that proxy, current to 2026-11-10.

Free

Get David Soergel’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track David Soergel and every company like it: Velarion Intel, free for 3 days, no card →

David Soergel compensation by year

MADRIGAL PHARMACEUTICALS Summary Compensation Table · the one fiscal year held
In US dollars, as MADRIGAL PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$418,182
Bonus$75,000
Stock awards$5,911,809
Option awards$2,201,587
Non-equity incentive$584,100
Pension and deferred compensation$0
All other$0
Total$9,190,678

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: MADRIGAL PHARMACEUTICALS, INC. DEF 14A filed April 28, 2026, accession 0001308179-26-000352, and prior-year filings.

How this page was built: the MADRIGAL PHARMACEUTICALS, INC. filed document, accession 0001308179-26-000352. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2026.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
PSU15,090$8,787,511—
RSU7,545$4,393,755—
Option12,839—$291.82

Per the Outstanding Equity Awards at Fiscal Year-End table in MADRIGAL PHARMACEUTICALS, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

2 Form 4 lines since the FY2025 proxy (filed April 28, 2026)
current to 2026-11-10 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-06-01Sale10b5-11,042$495.7410,033
2026-05-18Sale—844$515.9011,075

The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

MADRIGAL PHARMACEUTICALS’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Bill SiboldPresident and Chief Executive Officer$19,206,341
David Soergel · this pageExecutive Vice President and Chief Medical Officer$9,190,678
Rebecca TaubSenior Scientific and Medical Advisor and Former President, Research & Development and Chief Medical Officer$6,868,016
Mardi DierExecutive Vice President and Chief Financial Officer$6,085,089
Carole HuntsmanExecutive Vice President and Chief Commercial Officer$5,441,736
Shannon KelleyExecutive Vice President and Chief Legal Counsel$5,179,352

David Soergel's compensation dossier, MADRIGAL PHARMACEUTICALS

You have read David Soergel's totals and holdings. The dossier adds each equity grant MADRIGAL PHARMACEUTICALS disclosed for David Soergel and MADRIGAL PHARMACEUTICALS's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.

See an example →

The full MADRIGAL PHARMACEUTICALS compensation record

free company brief
MADRIGAL PHARMACEUTICALS, INC. (MDGL) — free Compensation Briefevery named executive and director, board pay, say-on-pay, the peer group

This page is one person within MADRIGAL PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the MADRIGAL PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order MADRIGAL PHARMACEUTICALS's full Executive Compensation Report with peer benchmarking.

Open the Daily Digestfree · newest disclosures
How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are MADRIGAL PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

David Soergel's compensation dossier